NEW CHIEF FINANCIAL OFFICER
Vancouver, British Columbia, January 22, 2001 - Response Biomedical Corp.
(RBM: CDNX) today announced the appointment of Mr. Robert Pilz, B.Comm.,
CMA, to the position of Chief Financial Officer, effective immediately. Mr.
Bruce Colwill has left the Company to pursue new ventures.
Mr. Pilz brings over 12 years of corporate finance, planning, and strategic
partnering experience to Response Biomedical. Throughout his career, he has
specialized in managing business and financial processes within highly
competitive markets, both in large multi-national and emerging growth
technology companies. Previously, Mr. Pilz managed the development of the
Sales and Operations Planning process at Norske Skog Canada Ltd (NS:TSE,
formerly Fletcher Challenge Canada Ltd.).
"Mr. Pilz has the financial experience and leadership expertise that will be
invaluable to help make Response Biomedical a leading diagnostics company,"
said Bill Radvak, President and CEO. "Having Mr. Pilz join our team at this
critical time in our evolution gives me further confidence that our key
milestones will be met on schedule."
In his position, Mr. Pilz will focus on strategies to strengthen the
Company's financial position and opportunities for growth. In addition, he
will continue to develop and implement business planning and new
initiatives.
Response Biomedical develops quantitative, point-of-care, diagnostic tests
for use with its proprietary RAMP System. The RAMP System reduces the cost
of healthcare by allowing accurate, rapid, and easy-to-use tests to be
performed in hospitals, clinics, laboratories, and doctor's offices
worldwide.
The Canadian Venture Exchange has not reviewed and does not accept
responsibility for the adequacy of the content of the information contained
herein. The statements made in this press release may contain certain
forward-looking statements that involve a number of risks and uncertainties.
Actual events or results may differ from the Company's expectations.
For more information, please contact:
Ryan Males, Ph.D.
Investor Relations
Response Biomedical Corp.
604 681-4101 tel
604 412-9830 fax
rmales@responsebio.com
Joanna Longo, Investor Relations
The Equicom Group Inc.
416 815-0700 tel
416 815-0080 fax
jlongo@equicomgroup.com |
